文献速递心外重症与机械循环支持瓣膜外科

连续流左心室辅助装置植入同期行主动脉瓣修复的中期结局

Medium-term outcomes of concomitant aortic valve repair in patients with continuous-flow left ventricular assist device.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-05-25

回顾性分析2004至2022年接受HeartMate II或3植入并同期行中央型主动脉瓣修复的105例患者,术后1年、2年、3年免于中度及以上主动脉瓣反流分别为96.4%、93.3%、91.0%,3年生存率63.4%。作者认为中央型主动脉瓣修复可能有效减轻主动脉瓣反流,但需更大样本和更长随访进一步研究。

要点

  • 105例患者中,术前主动脉瓣反流程度为轻度57例、轻至中度25例、中度21例、中至重度1例、重度1例。
  • 术后1年、2年、3年免于中度及以上主动脉瓣反流分别为96.4%、93.3%、91.0%。
  • 3年生存率为63.4%,院内死亡率为5.7%(6例)。

核心结论

  • 中央型主动脉瓣修复可能是减轻HeartMate II和3患者主动脉瓣反流的有效技术。
  • 作者认为需要更大样本、更长随访的队列研究来进一步探究其临床效果。

研究设计与样本

  • 回顾性综述2004年至2022年接受HeartMate II或3植入的患者,排除有主动脉瓣手术史、二叶式主动脉瓣、基线微量主动脉瓣反流或同期其他主动脉瓣手术者。
  • 656例接受HeartMate II或3植入的患者中,105例(HeartMate II 59例,HeartMate 3 46例)符合研究标准,术前存在轻度及以上主动脉瓣反流并同期行主动脉瓣修复。

主要发现

  • 中位年龄68岁(60-74岁),男性占91.4%(96例),白人占54.4%(56例),68.6%(72例)以 destination therapy 接受支持。
  • 术前主动脉瓣反流程度:轻度54.3%(57例),轻至中度23.8%(25例),中度20.0%(21例),中至重度1.0%(1例),重度1.0%(1例)。
  • 院内死亡率为5.7%(6例)。
  • 术后1年、2年、3年免于中度及以上主动脉瓣反流分别为96.4%(95%CI 92.5%-100%)、93.3%(95%CI 87.6%-99.2%)、91.0%(95%CI 84.1%-98.5%)。
  • 1例接受HeartMate II的患者发生重度主动脉瓣反流并接受心脏移植;3年生存率为63.4%(95%CI 52.9%-75.9%)。

关键数值与推荐

  • 术前存在轻度或以上主动脉瓣反流者同期行主动脉瓣修复。
  • 排除标准包括有主动脉瓣手术史、二叶式主动脉瓣、基线微量主动脉瓣反流或同期其他主动脉瓣手术。
  • 术后1年、2年、3年免于中度及以上主动脉瓣反流分别为96.4%(95%CI 92.5%-100%)、93.3%(95%CI 87.6%-99.2%)、91.0%(95%CI 84.1%-98.5%)。
  • 3年生存率为63.4%(95%CI 52.9%-75.9%);院内死亡率为5.7%(6例)。

临床怎么用

  • 作者认为中央型主动脉瓣修复可能是减轻HeartMate II和3患者主动脉瓣反流的有效技术。
  • 作者认为需要更大样本、更长随访的队列研究来进一步探究其临床效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the development of aortic insufficiency in patients who received central aortic valve repair when undergoing continuous-flow left ventricular assist device implantation. METHODS: We conducted a retrospective review of patients who underwent implantation with HeartMate II or 3 (Abbott Laboratories) between 2004 and 2022. Ninety-four patients were excluded from analysis for history of aortic valve procedures, a bicuspid aortic valve, baseline trace aortic insufficiency, or other concomitant aortic valve procedure. Patients who had mild or greater aortic insufficiency had concomitant aortic valve repair. Clinical characteristics, serial echocardiograms, and outcomes were determined. RESULTS: Of the 656 patients who underwent HeartMate II or 3 implantation, 105 patients (59 HeartMate II and 46 HeartMate 3) met study criteria. Median age was 68 years (60-74 years), 91.4% (n = 96) were male, 54.4% (n = 56) were White, and 68.6% (n = 72) received support as destination therapy. Preoperative aortic insufficiency degree was 54.3% (n = 57) mild, 23.8% (n = 25) mild-to-moderate, 20.0% (n = 21) moderate, 1.0% (n = 1) moderate-to-severe, and 1.0% (n = 1) severe. In hospital mortality was 5.7% (n = 6). Freedom from moderate or greater aortic insufficiency was 96.4% (95% confidence interval [CI], 92.5%-100%), 93.3% (95% CI, 87.6%-99.2%), and 91.0% (95% CI, 84.1%-98.5%) at 1-year, 2-year, and 3-year postimplantation, respectively. One patient who received a HeartMate II experienced severe aortic insufficiency and was treated with a heart transplant. Three-year survival was 63.4% (95% CI, 52.9%-75.9%). CONCLUSIONS: Central aortic valve repair may be an effective technique to mitigate aortic insufficiency in HeartMate II and 3. A larger cohort study with longer duration of follow-up is warranted to further investigate the clinical effect.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hynds MA, Hayashi H, Kurlansky P, et al. Medium-term outcomes of concomitant aortic valve repair in patients with continuous-flow left ventricular assist device. J Thorac Cardiovasc Surg. 2024. PMID: 38802043. doi:10.1016/j.jtcvs.2024.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。